MX2020003418A - Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab. - Google Patents

Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.

Info

Publication number
MX2020003418A
MX2020003418A MX2020003418A MX2020003418A MX2020003418A MX 2020003418 A MX2020003418 A MX 2020003418A MX 2020003418 A MX2020003418 A MX 2020003418A MX 2020003418 A MX2020003418 A MX 2020003418A MX 2020003418 A MX2020003418 A MX 2020003418A
Authority
MX
Mexico
Prior art keywords
obituzumab
positive
treatment
cell lymphoma
lymphoma
Prior art date
Application number
MX2020003418A
Other languages
English (en)
Inventor
Michael Wenger
Mehrdad MOBASHER
Chin-Yu Lin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020003418A publication Critical patent/MX2020003418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a la velocidad de administración de obinutuzumab.
MX2020003418A 2017-10-19 2018-10-19 Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab. MX2020003418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
MX2020003418A true MX2020003418A (es) 2020-07-20

Family

ID=64362606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003418A MX2020003418A (es) 2017-10-19 2018-10-19 Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.

Country Status (12)

Country Link
US (1) US20200299398A1 (es)
EP (1) EP3697818A2 (es)
JP (2) JP6860652B2 (es)
KR (1) KR20200067196A (es)
CN (1) CN111212854A (es)
AU (1) AU2018303836A1 (es)
BR (1) BR112020007731A2 (es)
CA (1) CA3079374A1 (es)
IL (1) IL273909A (es)
MX (1) MX2020003418A (es)
TW (2) TWI828593B (es)
WO (1) WO2019017499A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020007731A2 (pt) * 2017-10-19 2020-10-20 F. Hoffmann-La Roche Ag composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo
AR122307A1 (es) * 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
CN117941219A (zh) 2021-09-17 2024-04-26 佳能株式会社 送电设备和受电设备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341009T3 (es) 2003-11-05 2010-06-14 Roche Glycart Ag Anticuerpos cd20 con afinidad de union a receptores fc y funcion efectora.
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
HRP20220738T1 (hr) * 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
BR112020007731A2 (pt) * 2017-10-19 2020-10-20 F. Hoffmann-La Roche Ag composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo

Also Published As

Publication number Publication date
IL273909A (en) 2020-05-31
JP2019528282A (ja) 2019-10-10
CA3079374A1 (en) 2019-01-24
US20200299398A1 (en) 2020-09-24
TWI805630B (zh) 2023-06-21
WO2019017499A3 (en) 2019-02-21
KR20200067196A (ko) 2020-06-11
TW201922284A (zh) 2019-06-16
WO2019017499A2 (en) 2019-01-24
JP7370357B2 (ja) 2023-10-27
TW202342099A (zh) 2023-11-01
AU2018303836A1 (en) 2020-05-14
TWI828593B (zh) 2024-01-01
CN111212854A (zh) 2020-05-29
JP2021152002A (ja) 2021-09-30
BR112020007731A2 (pt) 2020-10-20
EP3697818A2 (en) 2020-08-26
JP6860652B2 (ja) 2021-04-21

Similar Documents

Publication Publication Date Title
MX2020004287A (es) Procesamiento de biomasa.
MX2019015848A (es) Cubetas de lectura.
MX2020003441A (es) Transmision de referencia de sondeo.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
MX2020004060A (es) Metodos para el tratamiento de infeccion de hepatitis b.
MX2019000985A (es) Recomendacion de accesorio.
GEP20217331B (en) Anti-tigit antibodies
MX2020003760A (es) Formulaciones de niraparib.
MX2020003519A (es) Composicion de polipropileno reforzado con fibra.
MX2020003712A (es) Union giratoria de pasaje multiple.
MX2020003700A (es) Laminados elasticos con elasticos curvos y metodos para la fabricacion.
MX2020004424A (es) Formulacion aerosolizable.
MX2020003483A (es) Composiciones de pienso para animales mejoradas y metodos de uso.
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020003502A (es) Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2.
MX2020004072A (es) Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
MX2019009647A (es) Tapa para taza de pulpa moldeada.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
IL273909A (en) Treatment of CD20-positive B-cell lymphoma with obituzumab
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2020003617A (es) Dispositivo de preparacion de cables.
MX2020003531A (es) Soluciones de templado reactivo y metodos de uso.
MX2020004285A (es) Proceso para preparar el benzotiofen-2-il boronato.
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.